ArticleAmerican journal of translational research2023
High expression of KMT2D is a promising biomarker for poor gastric cancer prognosis.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 citations in OpenAlex.
- In vivo CRISPR knockout screen identifies Polr1a as a key driver and a potential therapeutic target for melanoma metastasis.Oncogene · 2026Article
- Enhancer and metabolic rewiring by KMT2C-COMPASS or KMT2D-COMPASS family loss in cancer creates druggable vulnerabilities.Nature reviews. Cancer · 2026Review
- Genomic Differences and Distinct TP53 Mutation Site-Linked Chemosensitivity in Early- and Late-Onset Gastric Cancer.Cancer medicine · 2025Article
- Recurrent retroperitoneal liposarcoma with multiple surgeries: a case report.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression of histone lysine N-methyltransferase 2D (KMT2D) in gastric cancer patients and its relationship with the prognosis.
methodsA total of 126 gastric cancer patients admitted to Hubei Provincial Hospital of TCM from January 2014 to June 2017 were selected as the research subjects, and patients' clinical data were analyzed retrospectively. First, the KMT2D mRNA or protein expression in the patient's tissue was detected using quantitative real-time PCR or immunohistochemistry. Afterwards, the relationship between the KMT2D protein expression and the prognosis of patients was analyzed using a Kaplan-Meier curve. Also, the predictive value of the KMT2D mRNA and protein expression for the prognosis and death rate of gastric cancer patients was evaluated using a receiver operating characteristic curve. Finally, the risk factors for poor prognosis and death of the gastric cancer patients were analyzed using a Cox regression analysis.
resultsOverall, the KMT2D mRNA expression level and positive rate of protein expression in the gastric cancer tissues were significantly higher than that in paracancerous tissues (
conclusionKMT2D is highly expressed in gastric cancer tissue and it is expected to be a potential biomarker for predicting the poor prognosis of gastric cancer patients.
Indexed as
Identifiers
37056814PMC10086919W4365478949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.